Cargando…

Repeated dose of prostaglandin E2 vaginal insert when the first dose fails

OBJECTIVE: To compare the obstetric and neonatal outcomes of patients treated with repeated-dose prostaglandin E2 (dinoprostone) vaginal insert when the first dose fails. MATERIALS AND METHODS: This retrospective study included 1.043 pregnant women who received dinoprostone for labor induction betwe...

Descripción completa

Detalles Bibliográficos
Autores principales: Karadağ, Ceyda, Esin, Sertaç, Tohma, Yusuf Aytaç, Yalvaç, Ethem Serdar, Başar, Tuğrul, Karadağ, Burak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962160/
https://www.ncbi.nlm.nih.gov/pubmed/33715333
http://dx.doi.org/10.4274/tjod.galenos.2021.34119
_version_ 1783665414832652288
author Karadağ, Ceyda
Esin, Sertaç
Tohma, Yusuf Aytaç
Yalvaç, Ethem Serdar
Başar, Tuğrul
Karadağ, Burak
author_facet Karadağ, Ceyda
Esin, Sertaç
Tohma, Yusuf Aytaç
Yalvaç, Ethem Serdar
Başar, Tuğrul
Karadağ, Burak
author_sort Karadağ, Ceyda
collection PubMed
description OBJECTIVE: To compare the obstetric and neonatal outcomes of patients treated with repeated-dose prostaglandin E2 (dinoprostone) vaginal insert when the first dose fails. MATERIALS AND METHODS: This retrospective study included 1.043 pregnant women who received dinoprostone for labor induction between November 2012 and August 2015. Pregnant women were divided into two groups according to the number of dinoprostone administrations: group 1, single-dose dinoprostone (n=1.000), and group 2, repeated-dose dinoprostone (n=43). Intrapartum, postpartum, and neonatal outcomes of the pregnant women were compared. RESULTS: Vaginal delivery rate was 65% in group 1 and 30.2% in group 2 (p=0.001). The need for the neonatal intensive care unit was found in 44 pregnant women (4.4%) in group 1 and 6 pregnant women (13.6%) in group 2 (p=0.006). CONCLUSION: When obstetric and neonatal data were evaluated in our study, we observed that dinoprostone administration was associated with increased cesarean rates and adverse neonatal outcomes with repeated-dose dinoprostone when the first dose failed.
format Online
Article
Text
id pubmed-7962160
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-79621602021-03-25 Repeated dose of prostaglandin E2 vaginal insert when the first dose fails Karadağ, Ceyda Esin, Sertaç Tohma, Yusuf Aytaç Yalvaç, Ethem Serdar Başar, Tuğrul Karadağ, Burak Turk J Obstet Gynecol Clinical Investigation OBJECTIVE: To compare the obstetric and neonatal outcomes of patients treated with repeated-dose prostaglandin E2 (dinoprostone) vaginal insert when the first dose fails. MATERIALS AND METHODS: This retrospective study included 1.043 pregnant women who received dinoprostone for labor induction between November 2012 and August 2015. Pregnant women were divided into two groups according to the number of dinoprostone administrations: group 1, single-dose dinoprostone (n=1.000), and group 2, repeated-dose dinoprostone (n=43). Intrapartum, postpartum, and neonatal outcomes of the pregnant women were compared. RESULTS: Vaginal delivery rate was 65% in group 1 and 30.2% in group 2 (p=0.001). The need for the neonatal intensive care unit was found in 44 pregnant women (4.4%) in group 1 and 6 pregnant women (13.6%) in group 2 (p=0.006). CONCLUSION: When obstetric and neonatal data were evaluated in our study, we observed that dinoprostone administration was associated with increased cesarean rates and adverse neonatal outcomes with repeated-dose dinoprostone when the first dose failed. Galenos Publishing 2021-03 2021-03-12 /pmc/articles/PMC7962160/ /pubmed/33715333 http://dx.doi.org/10.4274/tjod.galenos.2021.34119 Text en ©Copyright 2021 by Turkish Society of Obstetrics and Gynecology | Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Investigation
Karadağ, Ceyda
Esin, Sertaç
Tohma, Yusuf Aytaç
Yalvaç, Ethem Serdar
Başar, Tuğrul
Karadağ, Burak
Repeated dose of prostaglandin E2 vaginal insert when the first dose fails
title Repeated dose of prostaglandin E2 vaginal insert when the first dose fails
title_full Repeated dose of prostaglandin E2 vaginal insert when the first dose fails
title_fullStr Repeated dose of prostaglandin E2 vaginal insert when the first dose fails
title_full_unstemmed Repeated dose of prostaglandin E2 vaginal insert when the first dose fails
title_short Repeated dose of prostaglandin E2 vaginal insert when the first dose fails
title_sort repeated dose of prostaglandin e2 vaginal insert when the first dose fails
topic Clinical Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962160/
https://www.ncbi.nlm.nih.gov/pubmed/33715333
http://dx.doi.org/10.4274/tjod.galenos.2021.34119
work_keys_str_mv AT karadagceyda repeateddoseofprostaglandine2vaginalinsertwhenthefirstdosefails
AT esinsertac repeateddoseofprostaglandine2vaginalinsertwhenthefirstdosefails
AT tohmayusufaytac repeateddoseofprostaglandine2vaginalinsertwhenthefirstdosefails
AT yalvacethemserdar repeateddoseofprostaglandine2vaginalinsertwhenthefirstdosefails
AT basartugrul repeateddoseofprostaglandine2vaginalinsertwhenthefirstdosefails
AT karadagburak repeateddoseofprostaglandine2vaginalinsertwhenthefirstdosefails